

Doxorubicin liposomal (Doxil[®], Lipodox[®]) (Intravenous)

Document Number: IC-0031

Last Review Date: 01/06/2020

Date of Origin: 09/01/2010

Dates Reviewed: 12/2010, 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 02/2015, 01/2016, 01/2017, 01/2018, 01/2019, 01/2020

I. Length of Authorization

Coverage will be provided for six months and may be renewed.

Use in the treatment of Mycosis Fungoides or Sezary Syndrome will be limited to 8 cycles.

Use in the treatment of Hodgkin Lymphoma will be limited to 6 cycles.

Use in the treatment of Multiple Myeloma and Non-Hodgkin's Lymphoma is limited to 8 cycles.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Lipodox/Doxil 20mg injection: 2 vials every 28 days
- Lipodox/Doxil 50mg injection: 3 vials every 28 days

B. Max Units (per dose and over time) [HCPCS Unit]:

AIDS-related Kaposi sarcoma (KS):

- 5 billable units every 21 days

Multiple myeloma, Non-Hodgkin's Lymphoma:

- 8 billable units every 21 days

Mycosis Fungoides/Sezary Syndrome, T-Cell Lymphoproliferative Disorders:

- 10 billable units every 28 days

Ovarian Cancer, Soft Tissue Sarcoma, Breast Cancer, Uterine Cancer:

- 12 billable units every 28 days

Hodgkin Lymphoma:

- 8 billable units every 21 days

III. Initial Approval Criteria^{1,2,3,4,5,6,7,9,10,11,12}

Coverage is provided in the following conditions:

- AIDS-related Kaposi sarcoma (KS)[†]
- Multiple Myeloma[†]

- Ovarian Cancer (including Fallopian Tube, Primary Peritoneal, and Epithelial Ovarian Cancers)†‡
- Breast Cancer‡
- Classic Hodgkin Lymphoma‡
- Non-Hodgkin’s Lymphoma‡
 - B-Cell Lymphomas
 - Follicular Lymphoma (grade 1-2)
 - Diffuse Large B-cell Lymphoma (including histologic transformation of Marginal Zone Lymphoma to Diffuse Large B-cell Lymphoma)
 - Multicentric Castleman’s Disease
 - T-Cell Lymphomas
 - Peripheral T-Cell Lymphoma
 - Adult T-Cell Leukemia/Lymphoma
 - Hepatosplenic Gamma-Delta T-Cell Lymphoma
- Soft Tissue Sarcomas‡
 - Extremity/Superficial Trunk, Head/Neck
 - Retroperitoneal/Intra-Abdominal
 - Angiosarcoma
 - Pleomorphic rhabdomyosarcoma
 - Desmoid Tumors (Aggressive Fibromatosis)
- Uterine Sarcoma (including stromal, undifferentiated and leiomyosarcoma) ‡
- Uterine Endometrial Carcinoma (including Adenocarcinoma, Carcinosarcoma, Clear Cell Carcinoma, Serous Carcinoma, Undifferentiated/dedifferentiated carcinoma) ‡
- Primary Cutaneous Lymphomas‡
 - Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders
 - Mycosis Fungoides/Sezary Syndrome

†FDA Approved Indication(s); ‡Compendia recommended indication(s)

IV. Renewal Criteria^{1,2,3}

Coverage can be renewed based upon the following criteria:

- Patient continues to meet criteria identified in section III; **AND**
- Tumor response with stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: hand-foot syndrome, cardiomyopathy, secondary oral neoplasms, severe infusion related reactions, etc.

V. Dosage/Administration^{1,2,3,8,11,12}

Indication	Dose
------------	------

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®) Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management



AIDS-related Kaposi Sarcoma (KS)	20 mg/m ² given intravenously every 3 weeks until disease progression or unacceptable toxicity
Multiple Myeloma	30 mg/m ² given intravenously every 3 weeks (on day 4) for 8 cycles or until disease progression or unacceptable toxicity
Non-Hodgkin's Lymphoma	30 mg/m ² given intravenously every 3 weeks for 6 to 8 cycles
Mycosis Fungoides/Sezary Syndrome, T-Cell Lymphoproliferative Disorders	20-40 mg/m ² given intravenously every 4 weeks for up to 8 cycles
Ovarian Cancer/Soft Tissue Sarcoma/ Uterine Cancer	50 mg/m ² given intravenously every 4 weeks until disease progression or unacceptable toxicity
Breast Cancer	50 mg/m ² given intravenously every 4 weeks until disease progression or unacceptable toxicity
Hodgkin Lymphoma	10-15 mg/m ² given intravenously on days 1 and 8 every 21 days for 2 to 6 cycles

VI. Billing Code/Availability Information

HCPCS code:

- Q2049 – Injection, doxorubicin hydrochloride, liposomal, imported Lipodox, 10 mg: 1 billable unit = 10mg
- Q2050 - Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg : 1 billable unit = 10mg

NDC:

- Lipodox 20 mg/10 ml single dose vial: 47335-0082-xx
- Lipodox 50 mg/25 ml single dose vial: 47335-0083-xx
- Doxil 20 mg/10 ml single dose vial: 59676-0960-xx
- Doxil 50 mg/25 ml single dose vial: 59676-0960-xx

**Generic available from various manufacturers*

VII. References

1. Doxil [package insert]. Bedford, OH; ALZA Corporation; April 2017. Accessed December 2019.
2. Lipodox [package insert]. Mumbai, India; Sun Pharmaceuticals; May 2012. Accessed December 2019.
3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Doxorubicin liposomal. National Comprehensive Cancer Network, 2019. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network,

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management

Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed December 2019.

4. Sutton G., et al. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2005 Mar; 96(3):749-52.
5. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. *Ann Oncol.* 2007 Jun; 18(6):1071-9.
6. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer.* 2001 May; 37(7):870-7.
7. Pulini S, Rupoli S, Goteri G, et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. *Haematologica* 2007;92(5):686-689.
8. Doxorubicin Liposomal. *Clinical Pharmacology* [Internet]. Tampa (FL): Elsevier. c2019- [cited 2019 December 4]. Available from: <http://www.clinicalpharmacology.com>.
9. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. *J Clin Oncol.* 2001 Jul 15;19(14):3312-22.
10. Orłowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. *J Clin Oncol.* 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6.
11. Martino R, Perea G, Caballero MD, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. *Haematologica.* 2002 Aug;87(8):822-7.
12. Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. *Leuk Lymphoma.* 2006 Oct;47(10):2174-80.
13. CGS Administrators, LLC. Local Coverage Article: Billing and Coding: Doxorubicin, Liposomal; Doxil, Caelyx Doxorubicin hydrochloride, all lipid formulations - Q2049, Q2050 (A57280). Centers for Medicare & Medicaid Services, Inc. Updated on 09/19/2019 with effective date 09/26/2019. Accessed December 2019.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C46.0	Kaposi's sarcoma skin
C46.1	Kaposi's sarcoma soft tissue

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®) Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
©2020, Magellan Rx Management



ICD-10	ICD-10 Description
C46.2	Kaposi's sarcoma palate
C46.3	Kaposi's sarcoma of lymph nodes
C46.4	Kaposi's sarcoma gastrointestinal sites
C46.50	Kaposi's sarcoma of unspecified lung
C46.51	Kaposi's sarcoma of right lung
C46.52	Kaposi's sarcoma of left lung
C46.7	Kaposi's sarcoma of other sites
C46.9	Kaposi's sarcoma of unspecified site
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip
C47.3	Malignant neoplasm of peripheral nerves of thorax
C47.4	Malignant neoplasm of peripheral nerves of abdomen
C47.5	Malignant neoplasm of peripheral nerves of pelvis
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified
C48.0	Malignant neoplasm of retroperitoneum
C48.1	Malignant neoplasm of specified parts of peritoneum
C48.2	Malignant neoplasm of peritoneum, unspecified
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip
C49.3	Malignant neoplasm of connective and soft tissue of thorax
C49.4	Malignant neoplasm of connective and soft tissue of abdomen

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management



ICD-10	ICD-10 Description
C49.5	Malignant neoplasm of connective and soft tissue of pelvis
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue
C49.9	Malignant neoplasm of connective and soft tissue, unspecified
C50.011	Malignant neoplasm of nipple and areola, right female breast
C50.012	Malignant neoplasm of nipple and areola, left female breast
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast
C50.021	Malignant neoplasm of nipple and areola, right male breast
C50.022	Malignant neoplasm of nipple and areola, left male breast
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast
C50.111	Malignant neoplasm of central portion of right female breast
C50.112	Malignant neoplasm of central portion of left female breast
C50.119	Malignant neoplasm of central portion of unspecified female breast
C50.121	Malignant neoplasm of central portion of right male breast
C50.122	Malignant neoplasm of central portion of left male breast
C50.129	Malignant neoplasm of central portion of unspecified male breast
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management



ICD-10	ICD-10 Description
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast
C50.611	Malignant neoplasm of axillary tail of right female breast
C50.612	Malignant neoplasm of axillary tail of left female breast
C50.619	Malignant neoplasm of axillary tail of unspecified female breast
C50.621	Malignant neoplasm of axillary tail of right male breast
C50.622	Malignant neoplasm of axillary tail of left male breast
C50.629	Malignant neoplasm of axillary tail of unspecified male breast
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast
C50.821	Malignant neoplasm of overlapping sites of right male breast
C50.822	Malignant neoplasm of overlapping sites of left male breast
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.912	Malignant neoplasm of unspecified site of left female breast
C50.919	Malignant neoplasm of unspecified site of unspecified female breast
C50.921	Malignant neoplasm of unspecified site of right male breast
C50.922	Malignant neoplasm of unspecified site of left male breast
C50.929	Malignant neoplasm of unspecified site of unspecified male breast
C53.0	Malignant neoplasm of endocervix
C54.0	Malignant neoplasm of isthmus uteri
C54.1	Malignant neoplasm of endometrium
C54.2	Malignant neoplasm of myometrium
C54.3	Malignant neoplasm of fundus uteri
C54.8	Malignant neoplasm of overlapping sites of corpus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified
C55	Malignant neoplasm of uterus, part unspecified
C56.1	Malignant neoplasm of right ovary
C56.2	Malignant neoplasm of left ovary

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management

ICD-10	ICD-10 Description
C56.9	Malignant neoplasm of unspecified ovary
C57.00	Malignant neoplasm of unspecified fallopian tube
C57.01	Malignant neoplasm of right fallopian tube
C57.02	Malignant neoplasm of left fallopian tube
C57.10	Malignant neoplasm of unspecified broad ligament
C57.11	Malignant neoplasm of right broad ligament
C57.12	Malignant neoplasm of left broad ligament
C57.20	Malignant neoplasm of unspecified round ligament
C57.21	Malignant neoplasm of right round ligament
C57.22	Malignant neoplasm of left round ligament
C57.3	Malignant neoplasm of parametrium
C57.4	Malignant neoplasm of uterine adnexa, unspecified
C57.7	Malignant neoplasm of other specified female genital organs
C57.8	Malignant neoplasm of overlapping sites of female genital organs
C57.9	Malignant neoplasm of female genital organ, unspecified
C78.00	Secondary malignant neoplasm of unspecified lung
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
C81.10	Nodular sclerosis Hodgkin lymphoma, unspecified site
C81.11	Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.12	Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes
C81.13	Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes
C81.14	Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.15	Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.16	Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes
C81.17	Nodular sclerosis Hodgkin lymphoma, spleen
C81.18	Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites
C81.19	Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites
C81.20	Mixed cellularity Hodgkin lymphoma, unspecified site
C81.21	Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.22	Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes
C81.23	Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes
C81.24	Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.25	Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management

ICD-10	ICD-10 Description
C81.26	Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes
C81.27	Mixed cellularity Hodgkin lymphoma, spleen
C81.28	Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites
C81.29	Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites
C81.30	Lymphocyte depleted Hodgkin lymphoma, unspecified site
C81.31	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.32	Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes
C81.33	Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes
C81.34	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.35	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.36	Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes
C81.37	Lymphocyte depleted Hodgkin lymphoma, spleen
C81.38	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites
C81.39	Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites
C81.40	Lymphocyte-rich Hodgkin lymphoma, unspecified site
C81.41	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.42	Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes
C81.43	Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes
C81.44	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.45	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.46	Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes
C81.47	Lymphocyte-rich Hodgkin lymphoma, spleen
C81.48	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites
C81.49	Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites
C81.70	Other Hodgkin lymphoma, unspecified site
C81.71	Other Hodgkin lymphoma, lymph nodes of head, face and neck
C81.72	Other Hodgkin lymphoma, intrathoracic lymph nodes
C81.73	Other Hodgkin lymphoma, intra-abdominal lymph nodes
C81.74	Other Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.75	Other Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.76	Other Hodgkin lymphoma, intrapelvic lymph nodes
C81.77	Other Hodgkin lymphoma, spleen
C81.78	Other Hodgkin lymphoma, lymph nodes of multiple sites
C81.79	Other Hodgkin lymphoma, extranodal and solid organ sites

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management

ICD-10	ICD-10 Description
C81.90	Hodgkin lymphoma, unspecified, unspecified site
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face and neck
C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C81.97	Hodgkin lymphoma, unspecified, spleen
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites
C83.30	Diffuse large B-cell lymphoma, unspecified site
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face and neck
C83.32	Diffuse large B-cell lymphoma intrathoracic lymph nodes
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes
C83.37	Diffuse large B-cell lymphoma, spleen
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites
C84.00	Mycosis fungoides, unspecified site
C84.01	Mycosis fungoides, lymph nodes of head, face and neck
C84.02	Mycosis fungoides, intrathoracic lymph nodes
C84.03	Mycosis fungoides, intra-abdominal lymph nodes
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb
C84.06	Mycosis fungoides, intrapelvic lymph nodes
C84.07	Mycosis fungoides, spleen
C84.08	Mycosis fungoides, lymph nodes of multiple sites
C84.09	Mycosis fungoides, extranodal and solid organ sites
C84.10	Sezary disease, unspecified site
C84.11	Sezary disease, lymph nodes of head, face and neck
C84.12	Sezary disease, intrathoracic lymph nodes
C84.13	Sezary disease, intra-abdominal lymph nodes

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management

ICD-10	ICD-10 Description
C84.14	Sezary disease, lymph nodes of axilla and upper limb
C84.15	Sezary disease, lymph nodes of inguinal region and lower limb
C84.16	Sezary disease, intrapelvic lymph nodes
C84.17	Sezary disease, spleen
C84.18	Sezary disease, lymph nodes of multiple sites
C84.19	Sezary disease, extranodal and solid organ sites
C84.40	Peripheral T-cell lymphoma, unspecified site
C84.41	Peripheral T-cell lymphoma, lymph nodes of head, face and neck
C84.42	Peripheral T-cell lymphoma, intrathoracic lymph nodes
C84.43	Peripheral T-cell lymphoma, intra-abdominal lymph nodes
C84.44	Peripheral T-cell lymphoma, lymph nodes of axilla and upper limb
C84.45	Peripheral T-cell lymphoma, lymph nodes of inguinal region and lower limb
C84.46	Peripheral T-cell lymphoma, intrapelvic lymph nodes
C84.47	Peripheral T-cell lymphoma, spleen
C84.48	Peripheral T-cell lymphoma, lymph nodes of multiple sites
C84.49	Peripheral T-cell lymphoma, extranodal and solid organ sites
C84.90	Mature T/NK-cell lymphomas, unspecified, unspecified site
C84.91	Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face and neck
C84.92	Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes
C84.93	Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes
C84.94	Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb
C84.95	Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb
C84.96	Mature, T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes
C84.97	Mature T/NK-cell lymphomas, unspecified, spleen
C84.98	Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites
C84.99	Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site
C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face and neck
C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes
C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes
C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb
C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb
C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes
C84.Z7	Other mature T/NK-cell lymphomas, spleen

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management

ICD-10	ICD-10 Description
C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites
C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified sites
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face and neck
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face and neck
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region of lower limb
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes
C85.87	Other specified types of non-Hodgkin lymphoma, spleen
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites
C86.1	Hepatosplenic T-cell lymphoma
C86.2	Enteropathy-type (intestinal) T-cell lymphoma
C86.6	Primary cutaneous CD30-positive T-cell proliferations
C90.00	Multiple myeloma not having achieved remission
C90.02	Multiple myeloma, in relapse
C90.10	Plasma cell leukemia not having achieved remission
C90.12	Plasma cell leukemia in relapse
C90.20	Extramedullary plasmacytoma not having achieved remission
C90.22	Extramedullary plasmacytoma in relapse
C90.30	Solitary plasmacytoma not having achieved remission
C90.32	Solitary plasmacytoma in relapse
C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®)
Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management



ICD-10	ICD-10 Description
C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated) in relapse
D36.0	Benign neoplasm of lymph nodes
D47.Z2	Castleman disease
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue
R59.0	Localized enlarged lymph nodes
R59.1	Generalized enlarged lymph nodes
R59.9	Enlarged lymph nodes, unspecified
Z85.3	Personal history of malignant neoplasm of breast
Z85.43	Personal history of malignant neoplasm of ovary
Z85.71	Personal history of Hodgkin lymphoma
Z85.79	Personal history of other malignant neoplasm of lymphoid hematopoietic and related tissues
Z85.831	Personal history of malignant neoplasm of soft tissue

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Articles may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/Article):

Jurisdiction(s): 15	NCD/LCD/Article Document (s): A57280
https://www.cms.gov/medicare-coverage-database/search/article-date-search.aspx?DocID=A57280&bc=gAAAAAAAAAAAAA==	

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto Government Benefit Administrators, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC

DOXORUBICIN LIPOSOMAL (Doxil®, Lipodox®)
Prior Auth Criteria

Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction	Applicable State/US Territory	Contractor
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC

DOXORUBICIN LIPOSOMAL (Doxil[®], Lipodox[®])

Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management